AstraZeneca Takes COVID-19 Vaccine to China With BioKangtai Deal for 200M-Dose Capacity by 2021

Source: FiercePharma

Last week China was a notable missing element in AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. That has changed, according to a FiercePharma report.

AstraZeneca reached a licensing deal with Chinese firm BioKangtai to help provide its adenovirus vector-based COVID-19 vaccine candidate, created by the University of Oxford, to China, AstraZeneca said (Chinese) in a social media post on Thursday. The pair will also explore the possibility of producing the vaccine for other markets.

Read the full article.

Related Content